ondasdechoque.org
PT-BR

Erectile dysfunction · Single-group study · 2026

Which men with erection problems respond best to shockwave?

In this study of 219 men, about two in three (145) improved six months after shockwave twice a week for three weeks. Men under 65, without diabetes, with erection problems for under 36 months, or who had been helped by erection pills, were more likely to respond.

Two in three men improved
men with erection problems linked to blood flow
219
weeks of treatment, twice a week
3
months of follow-up
6

Good to know: No comparison group. The 7-point score for predicting response has not yet been tested in other clinics.

Anıl H, Yıldız A, Topuz AN, et al. Sexual Medicine, 2026 · Read the paper ↗

How this study worked

StartFollow-up219 people
One group was followed over time, without a comparison group. Each dot stands for 3 people.

What happened

Men who responded at six months

Response: erection hardness up by 1 point or more, or erection score up by 5 or more

145 of 219 men (66%) met the study's goal for improvement six months after treatment.
Show the numbers
GroupCountShare
Shockwave145 / 21966.2%

The treatment

Shockwave

Focused, twice a week for 3 weeks

Focused wavesMeet at a focal zone below the skin
Pulses
3,000 per session · spread over six spots on the shaft; 18,000 in all
Strength
0.09mJ/mm² · 3 per second
Numbing
Not mentioned
Device
Modus ESWT

Compared with: No comparison group

Settings are what each study used, not a prescription.

Who took part

219 men aged 18–80 with mild to moderate erection problems thought to come from blood flow, at two centres; none had had shockwave before.

Shockwave219 people

Side effects

The available results do not report side effects for this group.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Men aged 18–80 with clinically diagnosed vasculogenic erectile dysfunction, baseline IIEF-5 EF 11–21, EHS 2–3, stable ED ≥6 months and no prior Li-ESWT; 219 analyzed. The responder/nonresponder groups are post-treatment strata defined by six-month response, not treatment arms. Penile Doppler was not routine.

Low-intensity ESWT219enrolled

Prospective, nonrandomized, single-arm intervention; responder/nonresponder groups defined after 6-month response.

Response: ≥1-point EHS increase or ≥5-point IIEF-5 EF increase1 reported outcome
01
6 months after treatment completion

Six-month Li-ESWT treatment response

Response: ≥1-point EHS increase or ≥5-point IIEF-5 EF increase responders / cohort

Low-intensity ESWT145 / 219

145/219 patients (66.2%) met the prespecified response definition at six months. This is a single-arm response rate, not a comparative treatment effect.

Analysis details and source

Responders n=145; nonresponders n=74. IIEF-5 EF and EHS are separate components of the OR-based response definition.

Seven-item 0–7 point score1 reported outcome
02
Predicting response at 6 months

Clinical prediction score for six-month Li-ESWT response

Seven-item 0–7 point score points; response likelihood bands

One point each: cardiovascular risk factors present; age <65; FMD ≥5%; previous PDE5i benefit; cIMT <0.8 mm; no diabetes; ED duration <36 months. Reported response-rate bands: 0–2 points, 0–25%; 3–4, 34–60%; 5–7, 75–88.3%. AUC 0.819 (95% CI 0.762–0.877); cutoff 4.5, sensitivity 73%, specificity 77%, PPV 0.86, NPV 0.59, accuracy 74%.

Analysis details and source

The model is not externally validated; prediction applies to this cohort/device/protocol. ORs: no DM 2.67 (1.24–5.72); ED duration <36 months 2.23 (1.10–4.53); cIMT <0.8 2.04 (1.03–4.06); PDE5i benefit 2.47 (1.18–5.15); FMD ≥5% 2.57 (1.23–5.34); age <65 2.28 (1.07–4.83); CVD risk factors 2.23 (1.06–4.70). CAD was not independent (p=.118). Calibration: Hosmer–Lemeshow χ²=1.678, df=4, p=.795. Bootstrap internal validation (1,000 iterations) yielded AUC .82 (95% CI .76–.88); this is not external validation.

IIEF score2 reported outcomes
03
Before Li-ESWT

IIEF at baseline by eventual response status

IIEF score Source-reported mean±SD or median (IQR)

Nonresponders (n=74): 16.8±3.6; responders (n=145): 16.3±2.9; p=.266.

Analysis details and source

Responder status is a post-treatment prognostic stratum, not a randomized comparator; these contrasts are not causal effects.

04
Six months after Li-ESWT

IIEF at month 6 by response status

IIEF score Source-reported mean±SD or median (IQR)

Nonresponders (n=74): 18.2±3.9; responders (n=145): 21.7±3.5; p<.001.

Analysis details and source

Responder status is a post-treatment prognostic stratum, not a randomized comparator; these contrasts are not causal effects.

Erection Hardness Score (EHS), median (IQR)2 reported outcomes
05
Before Li-ESWT

EHS at baseline by eventual response status

Erection Hardness Score (EHS), median (IQR) Source-reported mean±SD or median (IQR)

Nonresponders (n=74): 2 (2–2); responders (n=145): 2 (2–3); p=.223.

Analysis details and source

Responder status is a post-treatment prognostic stratum, not a randomized comparator; these contrasts are not causal effects.

06
Six months after Li-ESWT

EHS at month 6 by response status

Erection Hardness Score (EHS), median (IQR) Source-reported mean±SD or median (IQR)

Nonresponders (n=74): 2 (2–2); responders (n=145): 3 (2–3); p<.001.

Analysis details and source

Responder status is a post-treatment prognostic stratum, not a randomized comparator; these contrasts are not causal effects.

Age (years)1 reported outcome
07
Single-predictor ROC analysis

Age ROC

Age (years) AUC (95% CI), cut-off, sensitivity and specificity (%)

AUC .67 (95% CI .60–.74); cutoff ≤63.5 years; sensitivity 59.5%, specificity 82.1%; p<.001.

Analysis details and source

Responder status is a post-treatment prognostic stratum, not a randomized comparator; these contrasts are not causal effects.

ED duration, months1 reported outcome
08
Single-predictor ROC analysis

ED duration ROC

ED duration, months AUC (95% CI), cut-off, sensitivity and specificity (%)

AUC .68 (95% CI .61–.76); cutoff ≤34.5 months; sensitivity 82.4%, specificity 41.4%; p<.001.

Analysis details and source

Responder status is a post-treatment prognostic stratum, not a randomized comparator; these contrasts are not causal effects.

Carotid intima-media thickness (cIMT), mm1 reported outcome
09
Single-predictor ROC analysis

cIMT ROC

Carotid intima-media thickness (cIMT), mm AUC (95% CI), cut-off, sensitivity and specificity (%)

AUC .70 (95% CI .62–.78); cutoff <.765 mm; sensitivity 82.4%, specificity 36.6%; p<.001.

Analysis details and source

Responder status is a post-treatment prognostic stratum, not a randomized comparator; these contrasts are not causal effects.

Flow-mediated dilation (FMD), %1 reported outcome
10
Single-predictor ROC analysis

FMD ROC

Flow-mediated dilation (FMD), % AUC (95% CI), cut-off, sensitivity and specificity (%)

AUC .74 (95% CI .66–.83); cutoff ≥4.8%; sensitivity 89.0%, specificity 60.8%; p<.001.

Analysis details and source

Responder status is a post-treatment prognostic stratum, not a randomized comparator; these contrasts are not causal effects.

How treatment was delivered
Li-ESWT protocol

Modus ESWT electrohydraulic generator with focusing probe, 0.09 mJ/mm², 3 Hz; 3,000 pulses/session twice weekly, 18,000 total over 3 weeks at six bilateral penile shaft sites. Active PDE5i was stopped with a one-month washout.

HARMS & TOLERABILITY

The accessible results do not report adverse events for the Li-ESWT cohort. This should not be read as evidence of no harms.

LIMITS OF THE ANALYSIS

No sham/control group; response model developed and tested in the same 219-person cohort with bootstrap internal validation only. No external validation. Vasculogenic ED was diagnosed clinically without routine penile Doppler, which may include mixed vascular phenotypes. Two centers/operators, self-reported/clinical outcomes, device-specific 3-week protocol.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • No sham/control group; response model developed and tested in the same 219-person cohort with bootstrap internal validation only. No external validation. Vasculogenic ED was diagnosed clinically without routine penile Doppler, which may include mixed vascular phenotypes. Two centers/operators, self-reported/clinical outcomes, device-specific 3-week protocol.
Research review

Source-linked critical reading

Single-arm intervention and prediction-model study

Reading depthMaterial consulted
Technical source record

Read full article, raw Tables 1–4, all figure captions, Li-ESWT protocol, exact six-month response definition, regression coefficients, score bands, discrimination/calibration and limitations.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and evidence base

Prospective, nonrandomized, single-arm interventional study at two centers, planned January 2024–January 2025. A seven-factor prediction score was derived.

Participants

Men aged 18–80 with clinical vasculogenic ED, IIEF-5 EF 11–21, EHS 2–3, stable ED ≥6 months, and no Li-ESWT prior treatment. Penile Doppler was not routinely used.

Intervention

Modus ESWT electrohydraulic focusing device; 0.09 mJ/mm², 3 Hz, 3,000 pulses twice weekly for three weeks (18,000 total) at six bilateral shaft sites.

Comparator

No sham or untreated comparator.

Outcomes

Response at six months was ≥1-point EHS increase OR ≥5-point IIEF-5 EF increase. 145/219 (66.2%) responded. Table 1 also compares post-response strata (nonresponders vs responders): baseline IIEF 16.8±3.6 vs 16.3±2.9 (p=.266), month-6 IIEF 18.2±3.9 vs 21.7±3.5 (p<.001); baseline EHS median (IQR) 2 (2–2) vs 2 (2–3) (p=.223), month 6 2 (2–2) vs 3 (2–3) (p<.001). These are responder/nonresponder differences after treatment, not causal comparisons.

Comparative findings

Score: one point each for CVD risk factors, age <65, FMD ≥5%, prior PDE5i benefit, cIMT <0.8 mm, no diabetes, ED <36 months. AUC 0.819 (95% CI 0.762–0.877); sensitivity 73%, specificity 77% at 4.5 cutoff. The four single-predictor ROC rows in Table 2 are separate from the final seven-item score: age AUC .67 (95% CI .60–.74), cutoff ≤63.5; ED duration .68 (.61–.76), ≤34.5 months; cIMT .70 (.62–.78), <.765 mm; and FMD .74 (.66–.83), ≥4.8%; each p<.001. The article reports Hosmer–Lemeshow χ²=1.678 (df=4), p=.795 and internal 1,000-iteration bootstrap AUC .82 (95% CI .76–.88), not external validation.

Harms

No adverse-event summary was found in accessible results.

Limitations

No control group; score developed/tested in same cohort with internal bootstrap only, no external validation; clinical diagnosis without routine Doppler; device/protocol-specific, potential operator/site differences.

Applicability

Results and score apply to this cohort and protocol; do not establish comparative efficacy or validated individual prediction.

Research needs

External validation in independent multicenter cohorts and controlled trials are necessary before clinical use of the score.

THE ORIGINAL SOURCE

Read the original article.

Development of a clinical scoring system to predict response to low-intensity shock wave therapy in clinically diagnosed vasculogenic erectile dysfunction: a prospective, non-randomized, single-arm, interventional study.

Anıl H, Yıldız A, Topuz AN, Kayra MV, Sözütok S, Altunkol A, Alma E, Topuz M, Bayazıt Y. · Sexual medicine · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →